Literature DB >> 3863811

Pefloxacin in acute exacerbations of chronic bronchitis.

F P Maesen, B I Davies, J P Teengs.   

Abstract

Forty-three patients admitted to hospital with acute purulent exacerbations of chronic bronchitis were treated with 400 mg pefloxacin twice daily for ten days. The first 20 patients were given the first dose of the drug as a 60 min intravenous infusion. Serum and sputum concentrations of pefloxacin were measured microbiologically at intervals on the first treatment day and the sputum was cultured before, during, and after the course of pefloxacin. Two patients died from unrelated causes during the follow-up and one refused to continue treatment. All strains of Haemophilus influenzae and Branhamella catarrhalis were eradicated at end-of-treatment but eight strains of Streptococcus pneumoniae and three of Pseudomonas aeruginosa were cultured and the sputum remained purulent despite the pefloxacin. Peak serum concentrations averaged approximately 4.5 mg/l after the infusion and 5 mg/l on oral administration, the corresponding sputum concentrations being 3.8 and 4.6 mg/l, respectively. MICs for H. influenzae were 0.06 mg/l, or less. Mode MICs for the pre- and post-treatment strains of Str. pneumoniae were 4 and 16 mg/l, and the corresponding values for Ps. aeruginosa were 2 and 16 mg/l. The poor results in pseudomonas and pneumococcal infections could largely be explained by the degree of resistance among these organisms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3863811     DOI: 10.1093/jac/16.3.379

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Penetration of pefloxacin into bronchial secretions.

Authors:  G Bonmarchand; J J Grès; G Lerebours; P Massari; J J Mayoux; A Montay; J Leroy
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  Penetration of ofloxacin from blood to sputum.

Authors:  B I Davies; F P Maesen; W H Geraedts; C Baur
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  The quinolones in chronic bronchitis.

Authors:  B I Davies; F P Maesen; J P Teengs; C Baur
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

Review 5.  The place of quinolones in the treatment of respiratory tract infections.

Authors:  J W van der Meer
Journal:  Pharm Weekbl Sci       Date:  1989-08-25

Review 6.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 7.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

8.  Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease.

Authors:  A Watanabe
Journal:  Infection       Date:  1991       Impact factor: 3.553

9.  [New oral quinolone compounds in chronic bronchitis].

Authors:  B I Davies; F P Maesen; J P Teengs; C Baur
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 10.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.